Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$346K Sell
985
-69
-7% -$24.6K 0.01% 383
2025
Q4
$347K Sell
1,054
-5,250
-83% -$1.67M 0.01% 381
2025
Q3
$1.78M Sell
6,304
-6,883
-52% -$2M 0.05% 306
2025
Q2
$3.68M Buy
13,187
+480
+4% +$136K 0.11% 226
2025
Q1
$3.96M Sell
12,707
-385
-3% -$114K 0.22% 73
2024
Q4
$3.41M Buy
13,092
+3,444
+36% +$1.02M 0.16% 81
2024
Q3
$3.11M Buy
9,648
+133
+1% +$43.5K 0.2% 86
2024
Q2
$2.97M Hold
9,515
0.21% 78
2024
Q1
$2.7M Buy
9,515
+540
+6% +$158K 0.18% 86
2023
Q4
$2.58M Sell
8,975
-68
-0.8% -$18.5K 0.19% 86
2023
Q3
$2.43M Hold
9,043
0.21% 78
2023
Q2
$2.01M Hold
9,043
0.15% 91
2023
Q1
$2.19M Buy
9,043
+2,700
+43% +$663K 0.19% 82
2022
Q4
$1.67M Buy
6,343
+400
+7% +$107K 0.16% 85
2022
Q3
$1.34M Buy
5,943
+65
+1% +$15.8K 0.15% 83
2022
Q2
$1.43M Sell
5,878
-50
-0.8% -$12.3K 0.13% 81
2022
Q1
$1.43M Sell
5,928
-310
-5% -$71.2K 0.1% 88
2021
Q4
$1.4M Buy
6,238
+75
+1% +$15.8K 0.09% 98
2021
Q3
$1.31M Buy
6,163
+300
+5% +$69K 0.1% 90
2021
Q2
$1.43M Buy
+5,863
New +$1.44M 0.09% 88

Other funds holding AMGN

CSM Advisors's AMGN Position: Q1 2026 in Review

CSM Advisors reduced its Amgen (AMGN) stake by 6.5% in Q1 2026, selling an estimated $24.6K and leaving 985 shares worth $346K. The position accounts for 0.01% of the portfolio, ranked #383.

CSM Advisors first reported a position in AMGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $3.96M in Q1 2025. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • CSM Advisors held 985 shares of Amgen worth $346K as of Q1 2026.
  • CSM Advisors sold 69 Amgen shares in Q1 2026, an estimated $24.6K.
  • Amgen made up 0.01% of CSM Advisors's portfolio in Q1 2026, its #383 holding.
  • CSM Advisors first reported a position in Amgen in Q2 2021 and has held it in 20 quarters since.
  • CSM Advisors's Amgen position peaked at $3.96M in Q1 2025.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on CSM Advisors's 13F filing for Q1 2026, filed 15 May 2026.